ClinicalTrials.Veeva

Menu

Forxiga CKD Japan Post-Marketing Surveillance (PMS)

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Chronic Kidney Disease

Study type

Observational

Funder types

Industry

Identifiers

NCT05306210
D169AC00007

Details and patient eligibility

About

To capture safety when Forxige is administrated to CKD patients in the real world setting

Full description

The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch for treatment of CKD.

  1. ADRs which are unexpected from the precautions for use in our JPI
  2. Understanding of incidence of ADRs during use of Forxiga in the real world setting
  3. Factors (ie demography, treatment) possibly having an impact on the safety.

Enrollment

1,029 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with CKD except for dialysis and/or renal failure chronic

Exclusion criteria

  • None

Trial contacts and locations

46

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems